MRK · News · 20260823N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-08-23 · Importance 56 · Surprise 42

Third-party reports continue to identify Keytruda’s upcoming loss of exclusivity as a competitive risk for Merck’s oncology franchise. One report specifies an impending 2028 patent expiration, which could increase exposure to follow-on competition after Keytruda’s exclusivity period. The risk is being weighed alongside positive Phase 3 results for Merck’s personalized cancer therapy and generally positive analyst sentiment.

Key facts

• Some analysts expressed concern about Merck & Co., Inc.'s Keytruda loss of exclusivity and its potential valuation impact. source